Please ensure Javascript is enabled for purposes of website accessibility

Mazor Robotics Starts Its "Transition" Year Strong

By Brian Feroldi - May 15, 2018 at 4:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Business is booming for the robotic surgery upstart.

Mazor Robotics (MZOR) reported its first-quarter results on Monday, May 14. Last quarter, the robotic surgery company's management warned investors that 2018 was going to be a "transition" year because of its decision to strike a significant commercial deal with medical device giant Medtronic (NYSE: MDT). Management said that the deal was a huge win for the company, but it was going to result in "modest revenue growth" in 2018.

How did the company's actual growth shake out during the period? Let's dig into the details to find out.

A surgeon with a mask on standing in an operating room.

Image source: Getty Images.

Mazor Robotics Q1 results: The raw numbers

Metric

Q1 2018

Q1 2017

Year-Over-Year Change

Revenue

$15.5 million

$11.7 million

32%

Non-GAAP Net income

$340,000

($3.9 million)

N/A

Non-GAAP EPS

$0.01

($0.08)

N/A

GAAP = Generally Accepted Accounting Principles. Data source: Mazor Robotics.

What happened with Mazor Robotics this quarter?

  • U.S. revenue jumped 27% to $14.2 million. The gains were driven mostly by increased sales of the company's disposable products and service contracts. Capital sales were $6.6 million in the quarter, which was up just 2% year over year. The small jump in capital sales was owed to the company's lower per-system rate because of its distribution agreement with Medtronic.
  • International sales jumped 160% to $1.3 million.
  • Gross margin declined by 6.3 percentage points to 58.3%. The fall was mostly a result of the company's pricing terms with Medtronic.
  • Operating expenses fell 21% to $10.5 million. The decline was attributable to the company's decision to transition its salesforce to Medtronic.
  • GAAP net loss was $1.3 million, or $0.02 per share.
  • Non-GAAP net income -- which excludes stock-based compensation -- was $340,000. This marks the company's second profitable quarter in a row.
  • Cash provided from operating activities was $2.7 million.
  • Cash balance at the quarter end was $114.5 million.
  • Mazor's installed base at the quarter end was 200 systems placed in 15 countries.

What management had to say

CEO Ori Hadomi credited Mazor's strong first-quarter performance to "continued global demand for the Mazor X and Renaissance systems." He also noted the company continues to gain strength in several key areas.

"Our performance, coupled with the growing number of peer-reviewed papers, presentations, and the interim data from our prospective studies, is transforming spine surgery in markets around the world," Hadomi said.

Hadomi also briefly commented on the progress that is being made with the company's joint research and development program with Medtronic.

"We are also advancing and expanding our technology development efforts with Medtronic, and I am pleased to share that commercialization of the Mazor X platform, which integrates Medtronic's Stealth navigation and offers a unique robot-guided implant solution that eliminates the need for guidewires, is expected at the end of 2018," Hadomi said.

Looking forward

Mazor's management team has never shared guidance with investors, but CFO Sharon Levita did reaffirm that the company will save about $13 million in 2018 as a result of its distribution agreement with Medtronic. Levita also restated that revenue growth is expected to accelerate after 2018, though investors were not provided with specific numbers.

Management also noted that the company is "making progress" with its decisions to focus on selling its Renaissance system to Ambulatory Surgery Centers (ASCs). The company noted that there are 5,000 ASCs in the U.S., so the opportunity ahead of Renaissance remains significant.

Finally, Hadomi also restated that 2018 is expected to be a transition year for Mazor as the company's commercial deal with Medtronic continues to play out. However, he remained steadfast in his belief that the company is setting itself up well for continued success.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mazor Robotics Ltd. Stock Quote
Mazor Robotics Ltd.
MZOR

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.